What side effects are associated with this type of intervention?

The most common treatments for asthma include inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and leukotriene receptor antagonists (LTRA). ICS can cause side effects such as oral thrush, hoarseness, and coughing. LABAs may lead to side effects like tremors, headaches, and palpitations. LTRAs, such as montelukast, can cause side effects including headaches, abdominal pain, and, in rare cases, mood changes. Combination therapies (ICS/LABA) may combine these side effects but are generally well-tolerated when used as prescribed.

What prior FDA approvals exist?

The FDA has approved several medications for the treatment of asthma that focus on improving adherence and control. Inhaled corticosteroids (ICS) such as fluticasone and budesonide are commonly prescribed for their anti-inflammatory effects. Long-acting beta agonists (LABAs) like salmeterol and formoterol are often used in combination with ICS to enhance bronchodilation and control symptoms. Combination inhalers, such as fluticasone/salmeterol (Advair) and budesonide/formoterol (Symbicort), are also approved to simplify treatment regimens and improve adherence. Additionally, biologics like omalizumab (Xolair) and mepolizumab (Nucala) are approved for severe asthma, targeting specific pathways in the immune response. These treatments, along with regular monitoring and support, are crucial for effective asthma management.

What other types of research exist?

Promising alternatives to Telehealthcare Medication Therapy Management for asthma patients include: 1) Digital inhalers with integrated sensors that track usage and provide real-time feedback, 2) Mobile health apps that offer personalized asthma action plans and reminders, 3) Community pharmacist-led interventions that provide face-to-face education and support, and 4) AI-driven platforms that analyze patient data to predict and prevent asthma exacerbations.

← Back to Search

Corticosteroid

Telehealthcare MTM for Asthma (MATCH Trial)

N/A

Waitlist Available

Led By Kathryn Blake, Pharm.D

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 12 through 35 years

Any activity limitation due to asthma; OR Asthma Control Test score ≤19

Must not have

Currently uses an ICS not compatible with the Propeller sensor

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial uses video calls and sensors to help young people with asthma take their medication regularly. It targets those who struggle with sticking to their prescribed treatment, aiming to improve their health by providing support and reminders.

Who is the study for?

This trial is for young adults aged 12-35 with uncontrolled asthma and poor medication adherence. Participants must have an Asthma Control Test score ≤19 or experience significant symptoms, use a compatible inhaler, speak English or Spanish, and be able to engage in telehealthcare.

What is being tested?

The MATCH study tests if Telehealthcare Medication Therapy Management (MTM) via video calls and Electronic Adherence Self-Management (EAM) can improve medication adherence in adolescents and young adults with poorly controlled asthma.

What are the potential side effects?

Since the interventions involve management techniques rather than medications, direct side effects are not expected. However, participants may experience discomfort or privacy concerns related to using technology for health monitoring.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 12 and 35 years old.

Select...

My asthma limits my activities or my Asthma Control Test score is 19 or less.

Select...

I use my rescue inhaler more than twice a week for symptoms.

Select...

My asthma is uncontrolled, showing symptoms or limitations frequently.

Select...

I have been diagnosed with asthma and have no other lung diseases.

Select...

I experience asthma symptoms more than twice a week during the day.

Select...

I have been on inhaled corticosteroids for at least 3 months.

Select...

I use an albuterol inhaler for sudden asthma symptoms.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My inhaler is not compatible with the Propeller sensor.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of adherent days as assessed by Propeller sensors

Time (days) to first exacerbation event

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: MTM-EAMExperimental Treatment2 Interventions

Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management \[MTM-EAM\]

Group II: EAM onlyActive Control1 Intervention

Electronic Adherence Self-Management \[EAM\] only

0 / 9Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common asthma treatments include inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA). ICS work by reducing inflammation in the airways, LABAs relax the muscles around the airways to improve airflow, and LAMAs block muscarinic receptors to prevent bronchoconstriction. These mechanisms are vital for asthma patients as they help manage symptoms, prevent exacerbations, and improve lung function, thereby enhancing quality of life and reducing the risk of hospitalizations.